Skip to main content

Table 1 Baseline patient characteristics and MTX- and 6-MP-associated gene polymorphisms

From: Metabolic profiling reveals metabolic features of consolidation therapy in pediatric acute lymphoblastic leukemia

Characteristics

 

Sex: F/M, N

15/12

Age rage in months, median (IQR)

13–152, 69 (44–132)

Risk group, N (%)a

Standard: 12 (44.4)

Intermediate: 15 (55.6)

MRD46, N (%)b

< 0.01%: 23 (85.2)

≥ 0.01% < 0.1%: 3 (11.1)

> 0.1%: 1 (3.7)

  1. aRisk group was assigned based on age, leukocyte count, immunophenotype, central nervous system status, karyotype analysis, molecular status, and end-induction minimal residual disease (MRD) levels
  2. bMRD46 (day 46) was determined on day 21 (±2) after cyclophosphamide, cytarabine, and 6-MP chemotherapy